Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 Combined with Docetaxel or HB1801 in sqNSCLC
NCT06319313Phase 3Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- May 2024
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of becotatug in squamous cell carcinoma of the lung (SCCL), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start May 2024; status: not yet recruiting.
02
Drugs
becotatug
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT06319313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319313.